LIVN: Double-digit revenue growth and a return to profitability, driven by segment expansion and cost controls
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw double-digit revenue growth and a return to profitability, with net income of $108.6 million and strong performance in both Cardiopulmonary and Neuromodulation segments. Key developments included FDA approval for the aura6000 System, a favorable Italian tax ruling, and reduced debt.Original document: LivaNova PLC [LIVN] SEC 10-Q Quarterly Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw double-digit revenue growth and a return to profitability, with net income of $108.6 million and strong performance in both Cardiopulmonary and Neuromodulation segments. Key developments included FDA approval for the aura6000 System, a favorable Italian tax ruling, and reduced debt.
Original document: LivaNova PLC [LIVN] SEC 10-Q Quarterly Report — Aug. 5 2026